# Adapting Primary Care Panel Management for Non-Invasive NAFLD Risk Stratification: A Cluster Randomized Trial

## Metadata

- **SPORE ID**: SPR-2026-10B6
- **Domaines**: Liver Disease Diagnosis and Treatment x Primary Care and Health Outcomes
- **Date de generation**: 2026-08-27
- **Panel consensus score**: 6.5/10
- **Novelty score**: 0.8/1.0
- **Panel verdict**: publish_brief

## Abstract

Implementing a primary care-based panel management pathway that integrates FIB-4 and cardiometabolic risk assessment will increase the proportion of NAFLD patients with appropriate fibrosis monitoring or referral by 25-40% at 12 months, compared to usual care, because it systematically applies risk stratification and proactive outreach.

The proposed mechanism involves 5 causal steps: (1) Primary care staff receive training on NAFLD risk stratification using FIB-4 and -> (2) Electronic health record (EHR) prompts trigger FIB-4 calculation for at-risk pat -> (3) Patients with FIB-4 >1.3 (or age-adjusted thresholds) are flagged for proactive  -> (4) During visits, patients receive lifestyle counseling and, if indicated, referral.

Literature grounding on 11 verified references yields a novelty score of 0.8 (novel). A 3-phase experimental protocol (budget: €20k-100k, timeline: 12-18 months) is proposed, starting with in silico validation. A panel of 5 expert reviewers reached a consensus score of 6.5/10.

## 1. Hypothese et mecanisme propose

### 1.1 Formulation formelle

Implementing a primary care-based panel management pathway that integrates FIB-4 and cardiometabolic risk assessment will increase the proportion of NAFLD patients with appropriate fibrosis monitoring or referral by 25-40% at 12 months, compared to usual care, because it systematically applies risk stratification and proactive outreach.

### 1.2 Variables

**Variables independantes :**

| Variable | Type | Plage | Unite |
|----------|------|-------|-------|
| Intervention group | categorical | 0=usual care, 1=panel management | binary |

**Variables dependantes :**

| Variable | Type | Direction attendue | Unite |
|----------|------|-------------------|-------|
| Proportion of patients with appropriate fibrosis monitoring or referral | continuous | increase | percentage points |

### 1.3 Chaine causale

1. Step 1: Primary care staff receive training on NAFLD risk stratification using FIB-4 and cardiometabolic risk factors.
1. Step 2: Electronic health record (EHR) prompts trigger FIB-4 calculation for at-risk patients (e.g., with diabetes, obesity, or elevated ALT).
1. Step 3: Patients with FIB-4 >1.3 (or age-adjusted thresholds) are flagged for proactive outreach and scheduled for shared decision-making visits.
1. Step 4: During visits, patients receive lifestyle counseling and, if indicated, referral to hepatology or further non-invasive testing (e.g., elastography).
1. Step 5: Panel management ensures follow-up and tracking of patients, leading to higher rates of appropriate monitoring/referral.

**Hypotheses cles :**

- FIB-4 is a valid and reliable non-invasive marker for fibrosis risk in primary care populations.
- Primary care staff can be trained to implement the pathway with fidelity.
- EHR prompts are effectively integrated into clinical workflows.
- Patients are willing to attend shared decision-making visits.

**Inconnues identifiees :**

- The optimal age-adjusted FIB-4 thresholds for different age groups.
- The long-term impact of the pathway on clinical outcomes such as cirrhosis or mortality.
- Potential barriers to implementation in diverse primary care settings.

### 1.4 Conditions aux limites

- **Primary care clinics must have EHR capabilities to support FIB-4 calculation and patient tracking.** — The intervention relies on EHR prompts and panel management tools.
- **FIB-4 thresholds must be age-adjusted (e.g., >1.3 for <65 years, >2.0 for ≥65 years) to avoid misclassification.** — FIB-4 performance varies with age; age-adjusted thresholds improve diagnostic accuracy.
- **The intervention is limited to patients with NAFLD defined by imaging or biopsy, and without other liver diseases.** — The pathway is specific to NAFLD; other etiologies may require different management.

### 1.5 Cadre theorique

Chronic Care Model and Risk Stratification in Primary Care

## 2. Etat de l'art et positionnement

### 2.1 Travaux les plus proches

- **[2021] Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease** — [10.1053/j.gastro.2021.07.049](https://doi.org/10.1053/j.gastro.2021.07.049)
  - Similarite: related
  - Difference cle: This paper proposes a clinical care pathway for NAFLD risk stratification, but does not explicitly frame it as an adaptation of primary care's panel management approach for chronic diseases like diabetes.
- **[2019] Impact of Implementing a “FIB‐4 First” Strategy on a Pathway for Patients With NAFLD Referred From Primary Care** — [10.1002/hep4.1411](https://doi.org/10.1002/hep4.1411)
  - Similarite: related
  - Difference cle: This paper evaluates a FIB-4 first strategy in primary care, but does not explicitly link it to the broader primary care chronic disease management model (e.g., panel management, shared decision-making).

### 2.2 Base de preuves

- **[2021] Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease** — [10.1053/j.gastro.2021.07.049](https://doi.org/10.1053/j.gastro.2021.07.049)
  - Type: direct | Citations: 480
  - Provides a detailed clinical care pathway for NAFLD risk stratification and management, which aligns with the proposed adaptation of primary care frameworks.
- **[2019] Impact of Implementing a “FIB‐4 First” Strategy on a Pathway for Patients With NAFLD Referred From Primary Care** — [10.1002/hep4.1411](https://doi.org/10.1002/hep4.1411)
  - Type: direct | Citations: 77
  - Demonstrates the feasibility and impact of using FIB-4 as a first-line triage tool in primary care, supporting the proposed use of non-invasive fibrosis scores in primary care workflows.
- **[2016] Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score** — [10.1371/journal.pone.0147237](https://doi.org/10.1371/journal.pone.0147237)
  - Type: direct | Citations: 55
  - Shows that risk stratification of NAFLD in primary care is cost-effective, supporting the economic viability of the proposed integrated pathway.
- **[2020] Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study.** — [10.9778/cmajo.20200009](https://doi.org/10.9778/cmajo.20200009)
  - Type: direct | Citations: 35
  - Provides evidence that a primary care-accessible pathway using shear wave elastography can effectively risk-stratify NAFLD patients and reduce referrals, supporting the feasibility of such integrated pathways.
- **[2018] Non-alcoholic fatty liver disease and the interface between primary and secondary care.** — [10.1016/S2468-1253(18)30077-3](https://doi.org/10.1016/S2468-1253(18)30077-3)
  - Type: indirect | Citations: 127
  - Discusses the need for robust pathways for risk stratification in primary care, supporting the premise that primary care is the appropriate setting for NAFLD management.
- **[2022] Management of NAFLD in primary care settings** — [10.1111/liv.15404](https://doi.org/10.1111/liv.15404)
  - Type: indirect | Citations: 77
  - Reviews the role of primary care in NAFLD management, supporting the idea that primary care is pivotal in managing NAFLD and its comorbidities.
- **[2022] American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD).** — [10.1016/j.eprac.2022.03.010](https://doi.org/10.1016/j.eprac.2022.03.010)
  - Type: indirect | Citations: 836
  - Provides guidelines for NAFLD management in primary care, supporting the integration of non-invasive tests and risk stratification in primary care settings.
- **[2025] Population risk stratification tools and interventions for chronic disease management in primary care: a systematic literature review** — [10.1186/s12913-025-12690-0](https://doi.org/10.1186/s12913-025-12690-0)
  - Type: analogous | Citations: 22
  - Provides evidence on the use of risk stratification tools in primary care for chronic diseases, supporting the transferability of such approaches to NAFLD.
- **[2022] The Steatosis-Associated Fibrosis Estimator (SAFE) Score: A Tool to Detect Low-Risk Non-Alcoholic Fatty Liver Disease in Primary Care** — [10.1002/hep.32545](https://doi.org/10.1002/hep.32545)
  - Type: direct | Citations: 83
  - Develops and validates a non-invasive score for use in primary care to identify low-risk NAFLD, supporting the use of simple clinical indicators for risk stratification.
- **[2023] Nonalcoholic Fatty Liver Disease: Disease Burden and Disease Awareness.** — [10.1016/j.cld.2023.01.001](https://doi.org/10.1016/j.cld.2023.01.001)
  - Type: indirect | Citations: 30
  - Highlights the asymptomatic nature of NAFLD and the importance of high suspicion and noninvasive diagnosis in primary care, supporting the need for proactive screening.

### 2.3 Contre-preuves et limitations connues

- **[minor] Age-dependent differences in FIB-4 predictions of fibrosis in patients with MASLD referred from primary care**
  - Suggests that FIB-4 thresholds may not need to be adjusted for age, which could complicate risk stratification in elderly populations, but does not contradict the overall hypothesis.

### 2.4 Evaluation de nouveaute

- **Score**: 0.8/1.0
- **Verdict**: novel

## 3. Predictions falsifiables

| # | Prediction | Borne quantitative | Methode | H0 | Test statistique |
|---|-----------|-------------------|---------|-----|-----------------|
| 1 | The proportion of NAFLD patients with appropriate fibrosis monitoring or referral at 12 months will be 25-40% higher in the intervention group compared to usual care. | Absolute increase of 25-40 percentage points (e.g., from 20% to 45-60%) | Chart review or EHR extraction to determine if patients received FIB-4 testing, elastography, hepatology referral, or follow-up within 12 months. | H0: There is no difference in the proportion of patients with appropriate monitoring/referral between intervention and control groups. | Mixed-effects logistic regression with random effects for cluster (clinic), adjusting for baseline covariates, alpha=0.05 |

## 4. Protocole experimental

**Timeline globale**: 12-18 months
**Budget global**: €20k-100k

### 4.1 Phase 1 — In Silico Validation

**Objectif**: To determine whether the proposed intervention (panel management with FIB-4 and cardiometabolic risk assessment) is likely to increase appropriate monitoring/referral by 25-40% based on existing data and simulation, before committing to costly experimental trials.

**Methodologie**: Conduct a systematic review and meta-analysis of existing studies on NAFLD risk stratification in primary care, focusing on FIB-4 implementation and panel management. Use data from published trials (e.g., those in the evidence base) to model the expected effect size. Perform a simulation using Monte Carlo methods with parameters derived from the literature (e.g., baseline rates of appropriate monitoring, FIB-4 sensitivity/specificity, adherence to referral). Use EHR data from a partner clinic (if available) to validate the model. Tools: R or Python for statistical modeling, PRISMA guidelines for systematic review, metafor package in R for meta-analysis.

- Cout: €500-2000
- Duree: 4-6 weeks
- Equipement: Computer with internet access
- Logiciels: R or Python, Zotero or EndNote for reference management, PRISMA checklist

**Criteres de succes :**

- Predicted absolute increase in appropriate monitoring/referral from simulation: ≥25 percentage points (lower bound of hypothesis)
- Meta-analysis effect size (risk difference): ≥0.20 (20 percentage points) with confidence interval not crossing zero

- **GO**: Simulation predicts ≥25% increase and meta-analysis shows significant effect (lower bound >0)
- **NO-GO**: Simulation predicts <25% increase or meta-analysis shows no significant effect
- **PIVOT**: Simulation shows potential but requires modification (e.g., different FIB-4 threshold, additional risk factors)

### 4.2 Phase 2 — Minimal Experimental Validation

**Objectif**: To test the core mechanism of the intervention in a small, controlled setting: whether EHR prompts and staff training can increase FIB-4 testing and appropriate follow-up in a single clinic, providing proof-of-concept before a full trial.

**Methodologie**: Conduct a pilot study in one primary care clinic (or two matched clinics) with a pre-post design or small cluster randomization. Implement the panel management pathway: train staff, integrate EHR prompts for FIB-4 calculation, flag high-risk patients, and schedule shared decision-making visits. Measure the proportion of NAFLD patients receiving appropriate monitoring/referral over 3 months. Compare to baseline data from the same clinic (or a control clinic). Use a mixed-methods approach: quantitative data from EHR, qualitative interviews with staff to assess feasibility. Tools: EHR system (e.g., Epic, Cerner), REDCap for data collection, statistical analysis in R or SPSS.

- Cout: €2k-15k
- Duree: 1-3 months
- Equipement: Access to EHR system, Clinic space for training and visits
- Logiciels: EHR system with decision support capabilities, REDCap or similar for data capture, Statistical software (R, SPSS)

**Criteres de succes :**

- Increase in appropriate monitoring/referral from baseline: ≥10 percentage points (pilot effect, not necessarily full 25%)
- Fidelity of implementation: ≥80% of eligible patients receive FIB-4 testing and follow-up per protocol

- **GO**: Feasibility confirmed and preliminary effect ≥10% with no major barriers
- **NO-GO**: Implementation not feasible (e.g., staff resistance, EHR limitations) or effect <10%
- **PIVOT**: Effect is promising but requires adjustments (e.g., refine prompts, additional training)

### 4.3 Phase 3 — Full Experimental Protocol

**Objectif**: To rigorously evaluate the intervention's effectiveness in a cluster randomized controlled trial across multiple primary care clinics, providing publishable evidence on the 25-40% increase in appropriate monitoring/referral.

**Methodologie**: Design a cluster randomized controlled trial (cRCT) with clinics as clusters. Randomize 10-20 clinics to intervention or usual care (1:1). Intervention: implement panel management pathway as in Phase 2, but with standardized training, EHR integration, and ongoing support. Control: usual care. Primary outcome: proportion of NAFLD patients with appropriate monitoring/referral at 12 months. Secondary outcomes: FIB-4 testing rates, hepatology referrals, patient outcomes (e.g., fibrosis progression). Use mixed-effects logistic regression to account for clustering. Sample size calculation based on Phase 2 effect size and intracluster correlation. Follow CONSORT guidelines for cluster trials. Tools: EHR data extraction, REDCap for data management, R or Stata for analysis.

- Cout: €15k-100k+
- Duree: 6-12 months
- Equipement: EHR systems across clinics, Training materials and personnel
- Logiciels: EHR decision support, REDCap, Statistical software (R, Stata)

**Criteres de succes :**

- Absolute increase in appropriate monitoring/referral: ≥25 percentage points (as hypothesized)
- Statistical significance: p<0.05 for the primary outcome

- **GO**: Phase 2 successful and funding secured; trial feasible with adequate recruitment
- **NO-GO**: Phase 2 failed or insufficient resources; ethical concerns arise
- **PIVOT**: Results show effect but smaller than expected; consider adaptive design or longer follow-up

### 4.4 Quick start : comment demarrer aujourd'hui

- **Peut demarrer maintenant**: Oui
- **Premiere action**: Begin a systematic literature search using PubMed and Cochrane Library for studies on FIB-4 implementation in primary care and panel management for NAFLD, using keywords: 'NAFLD', 'FIB-4', 'primary care', 'risk stratification', 'panel management'.
- **Outils**: PubMed, Cochrane Library, Zotero, R or Python
- **Donnees ouvertes**: PubMed, Cochrane Library, ClinicalTrials.gov for unpublished trial data

## 5. Analyse d'impact

### 5.1 Impact scientifique

Novelty score: 0.8/1.0 (novel)

### 5.2 Applications industrielles et marche

**Score industriel**: 6.5/10

**Forces :**
- Growing NAFLD/NASH market: prevalence ~25% globally, with a projected market size of $20-30B by 2025 for diagnostics and treatments; primary care is a high-volume entry point.
- Leverages existing EHR infrastructure and FIB-4 (cheap, widely available) to create a scalable, low-cost intervention that can be integrated into panel management workflows, offering a potential competitive advantage in care coordination.
- Phased validation reduces upfront risk and cost, aligning with typical corporate R&D stage-gate processes; potential for rapid commercialization if Phase 2 succeeds.

**Faiblesses :**
- Reimbursement uncertainty: no specific CPT codes for NAFLD risk stratification in primary care; payers may not cover the intervention, limiting revenue streams.
- Competition from established liver diagnostic companies (e.g., Echosens, Siemens) and digital health platforms (e.g., Owlstone Medical) that offer more advanced non-invasive tests; differentiation may be challenging.
- Clinical workflow integration barriers: primary care physicians are already overloaded; adding panel management tasks may face resistance, requiring significant training and change management.

**Recommandation**: Pursue a strategic partnership with a major EHR vendor (e.g., Epic, Cerner) to embed the FIB-4 panel management module, targeting integrated delivery networks and accountable care organizations. Simultaneously, engage with payers early to establish coverage and coding, and consider licensing the algorithm to diagnostic companies for broader reach. Focus on demonstrating ROI through reduced specialist referrals and improved patient outcomes to secure pilot contracts.

### 5.3 Opportunites de financement

| Programme | Agence | Fit | Budget type | Taux succes |
|-----------|--------|-----|-------------|-------------|
| Horizon Europe - Cluster 1: Health (Research and Innovation Actions) | European Commission | 0.9 | €5-10 million (for large consortia) | ~15% (varies by call) |
| ANR Generic Call (Appel à projets générique) | Agence Nationale de la Recherche (France) | 0.7 | €200k-500k (for smaller projects) | ~20% (varies by scientific committee) |
| NIH R01 (Research Project Grant) | National Institutes of Health (USA) | 0.6 | $500k-2 million per year (total costs) | ~20% (for new applications) |

- **Horizon Europe - Cluster 1: Health (Research and Innovation Actions)** (European Commission): This program funds implementation research for chronic disease management, aligning with the cluster RCT and health system focus. The phased approach fits the need for evidence-based interventions.
- **ANR Generic Call (Appel à projets générique)** (Agence Nationale de la Recherche (France)): The ANR supports innovative research projects, including implementation science. This could fund the initial phases (in silico and pilot) to generate preliminary data for larger EU funding.
- **NIH R01 (Research Project Grant)** (National Institutes of Health (USA)): If US partners are included, the NIH R01 could fund the full cluster RCT, especially with a focus on implementation science and health disparities. The phased approach is suitable for NIH's emphasis on preliminary data.

**Recommandation financement**: Position this as an implementation science proposal under Horizon Europe's Cluster 1 (Health) or the ANR's generic call, emphasizing the phased validation and potential for health system impact. For the full trial, seek funding from the EU's Horizon Europe 'Health' pillar or national agencies like the NIH (R01) if US partners are included. Start with a small pilot grant (e.g., ANR PRCE) to generate preliminary data for a larger cluster RCT.

## 6. Panel Review Summary

| Reviewer | Score | Verdict | Point cle |
|----------|-------|---------|-----------|
| methodologist | 6.5/10 | weak_accept | The protocol is thoughtfully structured in three phases, allowing for iterative validation and de-risking before a full-scale trial. |
| domain_expert | 8.0/10 | accept | The hypothesis is well-aligned with current guidelines and evidence supporting the use of FIB-4 in primary care for NAFLD risk stratification, as demonstrated by the cited literature. |
| contrarian | 4.0/10 | weak_reject | Addresses a clinically important gap: primary care management of NAFLD is often suboptimal, and systematic risk stratification could improve care. |
| industrialist | 6.5/10 | accept | Growing NAFLD/NASH market: prevalence ~25% globally, with a projected market size of $20-30B by 2025 for diagnostics and treatments; primary care is a high-volume entry point. |
| funding_strategist | 7.5/10 | accept | Addresses a significant public health burden (NAFLD) with a pragmatic, scalable intervention in primary care, aligning with health systems strengthening priorities. |

**Consensus score**: 6.5/10
**Verdict final**: publish_brief

### 6.1 Consensus

- The hypothesis addresses a significant clinical gap in NAFLD management and proposes a pragmatic, scalable intervention using existing EHR infrastructure and FIB-4.
- The phased validation approach (in silico, pilot, full trial) is well-structured and reduces risk, making it attractive to funders and feasible for implementation.

### 6.2 Points de desaccord

- The expected effect size of 25-40% is considered optimistic by some reviewers, while others see it as plausible given the intervention's systematic approach.
- The potential for low fidelity due to alert fatigue and workflow barriers is a major concern for the contrarian, but other reviewers believe it can be mitigated with proper training and process evaluation.

### 6.3 Critical path

The success of this hypothesis hinges on the fidelity of implementation in real-world primary care settings, particularly overcoming alert fatigue and ensuring consistent adoption of the panel management pathway.

**Recommandation finale**: The panel recommends proceeding with the pilot phase to gather preliminary data on feasibility and fidelity, while addressing methodological gaps such as contamination prevention, sample size calculation with ICC, and robust outcome ascertainment. The full cluster trial should be contingent on successful pilot results and a clear plan for process evaluation. The intervention shows promise for improving NAFLD care, but its real-world impact depends on overcoming implementation barriers.

## 7. Gap Manifest residuel

### 7.1 Data gaps

- Need for implementation research on how to integrate NAFLD screening into existing primary care workflows, including EHR integration and provider training.
- Need for studies evaluating the effectiveness of shared decision-making in NAFLD management in primary care.

### 7.2 Competence gaps

- Phase 1: Systematic review methodology
- Phase 1: Meta-analysis
- Phase 1: Statistical modeling (Monte Carlo simulation)
- Phase 2: Clinical informatics
- Phase 2: Primary care clinical staff (physicians, nurses)
- Phase 2: Biostatistician
- Phase 3: Clinical trial management
- Phase 3: Biostatistics
- Phase 3: Implementation science
- Phase 3: Primary care clinicians and staff

### 7.3 Epistemic gaps

- The optimal age-adjusted FIB-4 thresholds for different age groups.
- The long-term impact of the pathway on clinical outcomes such as cirrhosis or mortality.
- Potential barriers to implementation in diverse primary care settings.

## References

[1] F. Kanwal, J. Shubrook, et al. (2021). *Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease*. DOI: [10.1053/j.gastro.2021.07.049](https://doi.org/10.1053/j.gastro.2021.07.049)
[2] T. Davyduke, P. Tandon, et al. (2019). *Impact of Implementing a “FIB‐4 First” Strategy on a Pathway for Patients With NAFLD Referred From Primary Care*. DOI: [10.1002/hep4.1411](https://doi.org/10.1002/hep4.1411)
[3] E. B. Tapper, M. Hunink, et al. (2016). *Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score*. DOI: [10.1371/journal.pone.0147237](https://doi.org/10.1371/journal.pone.0147237)
[4] A. Shaheen, K. Riazi, et al. (2020). *Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study.*. DOI: [10.9778/cmajo.20200009](https://doi.org/10.9778/cmajo.20200009)
[5] E. Tsochatzis, P. Newsome (2018). *Non-alcoholic fatty liver disease and the interface between primary and secondary care.*. DOI: [10.1016/S2468-1253(18)30077-3](https://doi.org/10.1016/S2468-1253(18)30077-3)
[6] V. Wong, S. Zelber-Sagi, et al. (2022). *Management of NAFLD in primary care settings*. DOI: [10.1111/liv.15404](https://doi.org/10.1111/liv.15404)
[7] K. Cusi, S. Isaacs, et al. (2022). *American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD).*. DOI: [10.1016/j.eprac.2022.03.010](https://doi.org/10.1016/j.eprac.2022.03.010)
[8] Davide Golinelli, Valentina Pecoraro, et al. (2025). *Population risk stratification tools and interventions for chronic disease management in primary care: a systematic literature review*. DOI: [10.1186/s12913-025-12690-0](https://doi.org/10.1186/s12913-025-12690-0)
[9] Pimsiri Sripongpun, W. Kim, et al. (2022). *The Steatosis-Associated Fibrosis Estimator (SAFE) Score: A Tool to Detect Low-Risk Non-Alcoholic Fatty Liver Disease in Primary Care*. DOI: [10.1002/hep.32545](https://doi.org/10.1002/hep.32545)
[10] P. Golabi, V. Isakov, et al. (2023). *Nonalcoholic Fatty Liver Disease: Disease Burden and Disease Awareness.*. DOI: [10.1016/j.cld.2023.01.001](https://doi.org/10.1016/j.cld.2023.01.001)
[11] Shuen Sung, Mustafa Al-Karaghouli, et al. (2024). *Age-dependent differences in FIB-4 predictions of fibrosis in patients with MASLD referred from primary care*. DOI: [10.1097/HC9.0000000000000609](https://doi.org/10.1097/HC9.0000000000000609)

## Annexes

### A. Detailed Reviewer Reports

#### Methodologist

- **Score**: 6.5/10 | **Verdict**: weak_accept | **Confidence**: 0.8
- **Strengths**: The protocol is thoughtfully structured in three phases, allowing for iterative validation and de-risking before a full-scale trial.; The use of in silico simulation and pilot testing before the main trial is a rigorous approach to assess feasibility and refine the intervention.; The primary outcome is clearly defined and measurable via EHR data, and the hypothesis specifies a plausible effect size (25-40% absolute increase).
- **Weaknesses**: The protocol lacks explicit details on how contamination between intervention and control clinics will be prevented or accounted for in the cluster randomized trial.; The sample size calculation for the full trial is not provided, nor is the intracluster correlation coefficient (ICC) estimated, which is critical for cluster trials.; Potential biases such as selection bias (e.g., differential recruitment of clinics) and measurement bias (e.g., reliance on EHR data completeness) are not thoroughly addressed.
- **Questions**: How will the investigators ensure that control clinics do not adopt similar practices during the trial period, and what measures will be taken to monitor and adjust for contamination?; What is the estimated intracluster correlation coefficient (ICC) for the primary outcome, and how was the sample size of 10-20 clinics determined to achieve adequate power?; How will the protocol handle missing data and ensure that EHR data are complete and accurate for all patients, particularly those who may not have follow-up visits?
- **Recommendation**: The protocol is promising and well-structured, but requires more detailed planning for the cluster randomized trial, including explicit strategies to minimize contamination, a formal sample size calculation with ICC, and a robust data management plan. I recommend proceeding with the pilot phase to gather preliminary data, but the full trial should be contingent on addressing these methodological gaps.

#### Domain Expert

- **Score**: 8.0/10 | **Verdict**: accept | **Confidence**: 0.85
- **Strengths**: The hypothesis is well-aligned with current guidelines and evidence supporting the use of FIB-4 in primary care for NAFLD risk stratification, as demonstrated by the cited literature.; The proposed mechanism is logically coherent, following a stepwise approach from training to EHR prompts, risk stratification, shared decision-making, and follow-up, which is consistent with successful chronic care models.; The integration of cardiometabolic risk assessment alongside FIB-4 is a strength, as it addresses the systemic nature of NAFLD and aligns with the holistic approach recommended in primary care.
- **Weaknesses**: The hypothesis assumes that EHR prompts and training will lead to high fidelity implementation, but real-world primary care settings often face workflow and time constraints that may hinder adoption.; The expected effect size of 25-40% increase in appropriate monitoring/referral may be overly optimistic given the complexity of behavior change and patient engagement, as seen in similar chronic disease management interventions.; The hypothesis does not address potential disparities in access to care or the impact of social determinants of health on patient willingness to attend shared decision-making visits, which could affect generalizability.
- **Questions**: How will the intervention account for variations in primary care practice workflows and the potential for alert fatigue from EHR prompts, and what strategies will be employed to ensure sustained engagement from both staff and patients?; What is the evidence base for the specific age-adjusted FIB-4 thresholds proposed, and how will the intervention handle borderline cases where FIB-4 is in the indeterminate zone?; How will the trial measure and ensure the fidelity of the intervention across diverse primary care settings, and what are the plans for process evaluation to understand barriers and facilitators?
- **Recommendation**: The hypothesis is promising and well-grounded in existing literature. I recommend proceeding with a pilot study to assess feasibility and refine implementation strategies, with a focus on understanding barriers to adoption and measuring process outcomes. The trial design should include a robust process evaluation to inform scalability.

#### Contrarian

- **Score**: 4.0/10 | **Verdict**: weak_reject | **Confidence**: 0.8
- **Strengths**: Addresses a clinically important gap: primary care management of NAFLD is often suboptimal, and systematic risk stratification could improve care.; Uses a pragmatic cluster randomized design, which enhances generalizability and reduces contamination bias.
- **Weaknesses**: FAIL REASON #1: The primary outcome (proportion with appropriate monitoring/referral) is process-oriented and highly susceptible to measurement bias; without blinding of outcome assessors and clear, objective criteria, the 25-40% effect size may be inflated by differential documentation or coding practices between intervention and control clinics.; FAIL REASON #2: The causal chain assumes that EHR prompts and staff training will translate into behavior change, but prior studies show that EHR alerts are often ignored (alert fatigue) and primary care staff may not adhere to complex pathways; fidelity is likely to be low, especially in busy practices, leading to a null effect.; FAIL REASON #3: The intervention does not account for patient-level confounders such as socioeconomic status, health literacy, and competing comorbidities, which may influence both the likelihood of attending shared decision-making visits and the receipt of monitoring/referral; without adequate risk adjustment or stratification, the observed effect may be confounded.
- **Questions**: How will you ensure that outcome ascertainment is unbiased and that the definition of 'appropriate monitoring or referral' is applied consistently across clinics, given that FIB-4 thresholds are age-dependent and may be misinterpreted?; What is the expected intracluster correlation coefficient (ICC) for the primary outcome, and what is the estimated number of clusters needed to detect a 25-40% absolute increase with 80% power? If the ICC is high, the trial may be underpowered.
- **Recommendation**: To strengthen the hypothesis, the authors should pilot the intervention to assess fidelity and measure the actual effect size on a composite outcome that includes both process and intermediate clinical outcomes (e.g., change in FIB-4 score or elastography results). They should also incorporate a process evaluation to monitor implementation barriers and use a run-in period to exclude clinics with low baseline performance. Additionally, consider using a stepped-wedge design to improve statistical power and adjust for confounders using mixed-effects models.

#### Industrialist

- **Score**: 6.5/10 | **Verdict**: accept | **Confidence**: 0.65
- **Strengths**: Growing NAFLD/NASH market: prevalence ~25% globally, with a projected market size of $20-30B by 2025 for diagnostics and treatments; primary care is a high-volume entry point.; Leverages existing EHR infrastructure and FIB-4 (cheap, widely available) to create a scalable, low-cost intervention that can be integrated into panel management workflows, offering a potential competitive advantage in care coordination.; Phased validation reduces upfront risk and cost, aligning with typical corporate R&D stage-gate processes; potential for rapid commercialization if Phase 2 succeeds.
- **Weaknesses**: Reimbursement uncertainty: no specific CPT codes for NAFLD risk stratification in primary care; payers may not cover the intervention, limiting revenue streams.; Competition from established liver diagnostic companies (e.g., Echosens, Siemens) and digital health platforms (e.g., Owlstone Medical) that offer more advanced non-invasive tests; differentiation may be challenging.; Clinical workflow integration barriers: primary care physicians are already overloaded; adding panel management tasks may face resistance, requiring significant training and change management.
- **Questions**: What is the specific reimbursement pathway for FIB-4-based panel management in primary care, and how will we convince payers to cover the service?; How does this intervention compare in cost-effectiveness to existing NAFLD screening programs (e.g., using elastography) to justify adoption by healthcare systems?; What is the IP landscape for panel management algorithms in NAFLD, and can we secure patents on the decision-support logic to protect our advantage?
- **Recommendation**: Pursue a strategic partnership with a major EHR vendor (e.g., Epic, Cerner) to embed the FIB-4 panel management module, targeting integrated delivery networks and accountable care organizations. Simultaneously, engage with payers early to establish coverage and coding, and consider licensing the algorithm to diagnostic companies for broader reach. Focus on demonstrating ROI through reduced specialist referrals and improved patient outcomes to secure pilot contracts.

#### Funding Strategist

- **Score**: 7.5/10 | **Verdict**: accept | **Confidence**: 0.8
- **Strengths**: Addresses a significant public health burden (NAFLD) with a pragmatic, scalable intervention in primary care, aligning with health systems strengthening priorities.; Phased validation approach (in silico, pilot, full trial) reduces risk and is attractive to funders seeking evidence-based implementation.; Leverages existing EHR infrastructure and non-invasive biomarkers (FIB-4) to improve risk stratification, fitting current clinical guidelines.
- **Weaknesses**: TRL is relatively low (3-4) for the full trial phase, requiring preliminary validation before a large-scale cluster RCT.; Consortium lacks a health economist and implementation science expert, which are crucial for evaluating cost-effectiveness and scalability.; The 25-40% effect size may be overly optimistic; funders may question feasibility without strong preliminary data.
- **Questions**: How will you ensure generalizability across diverse primary care settings (e.g., rural vs. urban, different EHR systems) in the cluster trial?; What is the plan for patient and stakeholder engagement to enhance adoption and sustainability of the panel management pathway?; Have you considered integrating patient-reported outcomes and health equity metrics to strengthen the impact case?
- **Recommendation**: Position this as an implementation science proposal under Horizon Europe's Cluster 1 (Health) or the ANR's generic call, emphasizing the phased validation and potential for health system impact. For the full trial, seek funding from the EU's Horizon Europe 'Health' pillar or national agencies like the NIH (R01) if US partners are included. Start with a small pilot grant (e.g., ANR PRCE) to generate preliminary data for a larger cluster RCT.

### B. Semantic Scholar Search Queries

- [novelty] `NAFLD primary care fibrosis risk stratification` — Direct search for the core hypothesis of integrating fibrosis risk stratification in primary care for NAFLD
- [novelty] `non-invasive fibrosis scores primary care NAFLD` — Check if non-invasive fibrosis scores are already used in primary care settings for NAFLD
- [novelty] `panel management chronic disease NAFLD` — Search for existing applications of panel management to NAFLD
- [evidence] `FIB-4 NFS primary care referral pathway` — Find evidence on the use of FIB-4 and NFS in primary care to guide referrals
- [evidence] `NAFLD cardiometabolic comorbidity management primary care` — Evidence on managing cardiometabolic comorbidities in NAFLD within primary care
- [evidence] `shared decision-making chronic liver disease` — Evidence on shared decision-making in chronic liver disease management
- [cross_domain] `diabetes care model liver disease` — Explore precedents of applying diabetes care models to liver disease
- [cross_domain] `risk stratification asymptomatic chronic disease primary care` — Examine how risk stratification is used for other asymptomatic chronic diseases in primary care
- [cross_domain] `proactive outreach chronic disease management` — Look for proactive outreach strategies in chronic disease management that could be adapted

---

*Generated by SPORE (Systeme de Production d'Opportunites de Recherche par Exploration) on 2026-08-27*